New and Emerging Biomarkers in Cardiovascular Disease

Leah E. Cahill, Monica L. Bertoia, Sarah A. Aroner, Kenneth J. Mukamal, Majken K. Jensen

Research output: Contribution to journalReview articlepeer-review

16 Citations (Scopus)

Abstract

Cardiovascular disease (CVD) is the most common cause of death and disability worldwide. Therefore, great importance has been placed on the discovery of novel risk factors and metabolic pathways relevant in the prevention and management of CVD. Such research is ongoing and may continue to lead to better risk stratification of individuals and/or the development of new intervention targets and treatment options. This review highlights emerging biomarkers related to lipid metabolism, glycemia, inflammation, and cardiac damage, some of which show promising associations with CVD risk and provide further understanding of the underlying pathophysiology. However, their measurement methodology and assays will require validation and standardization, and it will take time to accumulate evidence of their role in CVD in various population settings in order to fully assess their clinical utility. Several of the novel biomarkers represent intriguing, potentially game-changing targets for therapy.

Original languageEnglish
Article number88
JournalCurrent Diabetes Reports
Volume15
Issue number11
DOIs
Publication statusPublished - Nov 22 2015

Bibliographical note

Publisher Copyright:
© 2015, Springer Science+Business Media New York.

ASJC Scopus Subject Areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint

Dive into the research topics of 'New and Emerging Biomarkers in Cardiovascular Disease'. Together they form a unique fingerprint.

Cite this